Rehabilitation for Patients With Pulmonary Arterial Hypertension
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients suffering from pulmonary arterial hypertension (PAH) frequently remain symptomatic despite medical therapy. Symptoms include breathlessness, poor exercise capacity and reduced quality of life.
In many other serious heart or lung diseases it has been shown that physical rehabilitation improves patient's fitness and quality of life. In PAH there are no clear guidelines and in general physical activity has traditionally been discouraged, although evidence for this advice is lacking. Interesting research project in Germany showed significant benefit for in-patient rehabilitation in PAH patients.
In this study we will perform a controlled clinical study of out-patient rehabilitation of patients with PAH. We hypothesize that physical training of patients will result in increased exercise capacity and improved quality of life.
| Condition | Intervention |
|---|---|
|
Pulmonary Arterial Hypertension |
Behavioral: Physical training Behavioral: No training |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
- Six minute walking distance [ Time Frame: 3 months ]
- New York Heart Association (NYHA) functional class [ Time Frame: 3 months ]
- Echocardiographic parameters [ Time Frame: 3 months ]
- Quality of life as assessed by the SF-36 [ Time Frame: 3 months ]
- Performance in cardiopulmonary exercise test [ Time Frame: 3 months ]
| Estimated Enrollment: | 45 |
| Study Start Date: | February 2008 |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Physical training
|
Behavioral: Physical training |
|
Placebo Comparator: 2
No physical training
|
Behavioral: No training |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All patients must satisfy current diagnostic criteria for pulmonary artery hypertension based on their historical right heart catheter data (within 4 years of study enrollment): Mean PAP >25mmHg at rest or >30mmHg with exercise, by a PCWP <= 15mmHg and by PVR >3 Wood Units.
- Willing and able to participate in 24 bi-weekly rehabilitation sessions, and medical follow-up.
- Stable dose of current PAH-specific medication for 3 months prior to enrollment.
- New York Heart Association (NYHA) Class II-III.
- Women of child-bearing age must demonstrate adequate contraception or undergo a pregnancy test.
Exclusion Criteria:
- Functional Class NYHA Class I or IV.
- PAH due to congenital heart disease, left heart disease, chronic lung diseases (VC or FEV1 < 60% of predicted) or chronic hypoxia.
- Acute intercurrent illness requiring hospital admission in the month proceeding screening.
- Any non-PAH medical condition likely to interfere with participation in rehabilitation, e.g. musculoskeletal disorders.
- Any uncontrolled or terminal non-PAH medical condition likely to interfere with completion of the study, according to the judgment of the study physician.
- Participation in another rehabilitation scheme within 6 months of enrollment in the study.
- Current participation in another clinical trial.
- Pregnancy or planned pregnancy during the study period.
Contacts and Locations
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00544726 History of Changes |
| Other Study ID Numbers: | rmc074491ctl |
| Study First Received: | October 15, 2007 |
| Last Updated: | April 6, 2008 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by Rabin Medical Center:
|
Rehabilitation |
Additional relevant MeSH terms:
|
Hypertension, Pulmonary Hypertension Lung Diseases |
Respiratory Tract Diseases Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 22, 2013